Tetragastrin (Synonyms: Cholecystokinin tetrapeptide; CCK-4)

Name: Tetragastrin
Brand: MedChemExpress
SKU: HY-125556
Rating: 4.5 (1 reviews)

Cat. No.: HY-125556 Pureza: 99.89%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion. Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist. Gastric mucosal protection.

Para uso exclusivo en investigación. No vendemos a pacientes.

Síntesis de péptidos personalizados

Tetragastrin Estructura química

No. CAS : 1947-37-1

Tamaño	Stock	Cantidad
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	Obtener un presupuesto
200 mg	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE Tetragastrin

•Nat Commun. 2025 Jul 1;16(1):5943. [Abstract]

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas Cholecystokinin Receptor:

Ver todas las isoformas

CCKAR CCKBR

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion^[1]. Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist^[2]. Gastric mucosal protection^[3].

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	1.4 1 Compound: CCK-4	Affinity against Cholecystokinin type B receptor expressed in CHO cells on rat brain. Affinity against Cholecystokinin type B receptor expressed in CHO cells on rat brain.	[PMID: 11020275]
CHO	EC₅₀	1.4 1 Compound: CCK-4	Affinity against Cholecystokinin type B receptor expressed in CHO cells on rat brain. Affinity against Cholecystokinin type B receptor expressed in CHO cells on rat brain.	[PMID: 11020275]

In Vitro

The antagonist of histamine H2-receptors, Cimetidine inhibits the stimulatory effect of histamine in vitro and activates Tetragastrin stimulation of the adenylate cyclase activity. Tetragastrin and histamine activate adenylate cyclase of the rat gastric mucosa via different receptors^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In inbred Wistar rats treated with N-methyl-N'-nitro-N-nitrosoguanidine, Tetragastrin (s.c.; 1 mg/kg; every other day) treatment significantly reduces the incidence and the number of adenocarcinomas, and has a significantly lower labelling index of the antral mucosa^[1].
Tetragastrin has potential for enhancing gastric mucosal protection associated with mucus secretion and/or mucus synthesis on the surface mucosa of rat gastric mucosa. A significant increase in the mucin content was noted in the mucus gel and surface mucosal layer. An increase in mucin in the mucus gel and surface mucosa would thus appear due to the administration of Tetragastrin^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Seven-week-old male Wistar rats, each weighing approximately 160 g^[3]
Dosage:	12, 120, or 400 μg/kg
Administration:	Administered subcutaneously (s.c.); followed by 50% ethanol-induced gastric injury
Result:	Caused a significant increase in mucin content in the corpus mucosa and prevented 50% ethanol-induced gastric mucosal damage in a dose-dependent manner.

Peso molecular

596.70

Fòrmula

C₂₉H₃₆N₆O₆S

No. CAS

1947-37-1

Appearance

Solid

Color

White to off-white

Sequence Shortening

WMDF-NH2

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvente y solubilidad

In Vitro:

DMSO : 8.33 mg/mL (13.96 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6759 mL	8.3794 mL	16.7588 mL
5 mM	0.3352 mL	1.6759 mL	3.3518 mL
10 mM	0.1676 mL	0.8379 mL	1.6759 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 99.89%

Select Batch:

Ficha de datos (277 KB) SDS (252 KB)

COA (250 KB) RP-HPLC (112 KB) MS (221 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. M Tatsuta, et al. Effect of 6-hydroxydopamine on gastric carcinogenesis and tetragastrin inhibition of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Cancer Res. 1989 Aug 1;49(15):4199-203. [Content Brief]

[2]. Nathalie Lara, et al. Pulmonary and systemic nitric oxide measurements during CCK-5-induced panic attacks. Neuropsychopharmacology. 2003 Oct;28(10):1840-5. [Content Brief]

[3]. Y Komuro,et al. Effects of tetragastrin on mucus glycoprotein in rat gastric mucosal protection. Gastroenterol Jpn. 1992 Oct;27(5):597-603. [Content Brief]

[4]. A A Karelin,et al. Tetragastrin activation of rat gastric mucosa adenyl cyclase in vitro. Biull Eksp Biol Med. 1981 Apr;91(4):440-1. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6759 mL	8.3794 mL	16.7588 mL	41.8971 mL
	5 mM	0.3352 mL	1.6759 mL	3.3518 mL	8.3794 mL
	10 mM	0.1676 mL	0.8379 mL	1.6759 mL	4.1897 mL

Tetragastrin Related Classifications

Metabolic Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tetragastrin1947-37-1Cholecystokinin tetrapeptide CCK-4CCK4CCK 4CCK-4Cholecystokinin ReceptorCCK ReceptorC-terminaltetrapeptidegastringastricInhibitorinhibitorinhibit

Productos vistos recientemente:

Nombre del producto

Requested Quantity *

Nombre del solicitante *

Saludo

Direcciòn del E-mail *

Número de teléfono *

Department

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

Observaciones

Nombre del producto

Lot #

Nombre del solicitante *

Direcciòn del E-mail *

Número de teléfono

Department *

Nombre de la Organizaciòn *

Country or Region *

Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

Tetragastrin (Synonyms: Cholecystokinin tetrapeptide; CCK-4)

Revisión del cliente

Tetragastrin Related Antibodies

1 Publications Citing Use of MCE Tetragastrin

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas Cholecystokinin Receptor:

Actividad biológica

Pureza y Documentación

Referencias

Revisión del cliente

Tetragastrin Related Antibodies

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

Tetragastrin Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report